Kentaro Tajima

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Future oncology (London, England)

Breast cancer (Tokyo, Japan)

International journal of environmental research and public health

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) (2024)
Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu Masuda
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Toyoki Moribe, Linghua Xu, Kentaro Tajima, Naohiro Yonemoto
Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan. Future oncology (London, England) (2023)
Kentaro Tajima, Tomofumi Ishikawa, Fumiko Matsuzaki, Aoi Noda, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano
Validity of Administrative Data for Identifying Birth-Related Outcomes with the End Date of Pregnancy in a Japanese University Hospital. International journal of environmental research and public health 19 (8) (2022)
Kentaro Tajima, Tomofumi Ishikawa, Aoi Noda, Fumiko Matsuzaki, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano
Development and validation of claims-based algorithms to identify pregnancy based on data from a university hospital in Japan. Current medical research and opinion 38 (9) (2022)
Kentaro Tajima, Masami Tsuchiya, Tomofumi Ishikawa, Taku Obara, Nariyasu Mano
Real-world anticancer medications for reproductive-age women with breast cancer by using a claims database in Japan. Future oncology (London, England) 17 (15) (2021)